Sonogenetic-Based Neuromodulation for the Amelioration of Parkinson's Disease

Sonogenetics is a promising strategy allowing the noninvasive and selective activation of targeted neurons in deep brain regions; nevertheless, its therapeutic outcome for neurodegeneration diseases that need long-term treatment remains to be verified. We previously enhanced the ultrasound (US) sensitivity of targeted cells by genetic modification with an engineered auditorysensing protein, mPrestin (N7T, N308S). In this study, we expressed mPrestin in the dopaminergic neurons of the substantia nigra in Parkinson's disease (PD) mice and used 0.5 MHz US for repeated and localized brain stimulation. The mPrestin expression in dopaminergic neurons persisted for at least 56 days after a single shot of adeno-associated virus, suggesting that the period of expression was long enough for US treatment in mice. Compared to untreated mice, US stimulation ameliorated the dopaminergic neurodegeneration 10-fold and mitigated the PD symptoms of the mice 4-fold, suggesting that this sonogenetic strategy has the clinical potential to treat neurodegenerative diseases.

Automated summary

Sonogenetics is a promising strategy for noninvasively activating targeted neurons in deep brain regions, but its therapeutic efficacy for long-term neurodegenerative diseases needs further validation. By genetically modifying dopaminergic neurons in Parkinson's disease (PD) mice to express mPrestin and using ultrasound stimulation, researchers successfully improved dopaminergic neurodegeneration by 10-fold and alleviated PD symptoms by 4-fold, indicating its potential for clinical treatment of neurodegenerative diseases.